⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ASBP News
Aspire Biopharma Holdings, Inc. Common Stock
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin
accessnewswire.com
ASBP
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks
accessnewswire.com
ASBP
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
accessnewswire.com
ASBP
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
accessnewswire.com
ASBP
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
accessnewswire.com
ASBP
Aspire Biopharma Announces Reverse Stock Split
accessnewswire.com
ASBP
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
accessnewswire.com
ASBP
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
accessnewswire.com
ASBP
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
accessnewswire.com
ASBP
Aspire Biopharma Provides Q3 2025 Business Update
accessnewswire.com
ASBP